CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 194 filers reported holding CYMABAY THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 1.14 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $772,368 | +36.2% | 51,802 | 0.0% | 0.01% | +50.0% |
| Q2 2023 | $567,232 | +248.5% | 51,802 | -1.0% | 0.00% | +300.0% |
| Q1 2022 | $162,771 | +68.4% | 52,338 | +97.6% | 0.00% | 0.0% |
| Q3 2021 | $96,685 | -31.9% | 26,489 | -15.2% | 0.00% | 0.0% |
| Q1 2021 | $141,884 | +61.6% | 31,252 | +104.4% | 0.00% | 0.0% |
| Q4 2020 | $87,782 | -43.4% | 15,293 | -28.6% | 0.00% | -50.0% |
| Q3 2020 | $154,965 | +27.4% | 21,404 | -38.6% | 0.00% | +100.0% |
| Q2 2020 | $121,665 | -4.8% | 34,861 | +39.6% | 0.00% | 0.0% |
| Q3 2019 | $127,841 | -57.3% | 24,969 | -40.3% | 0.00% | -66.7% |
| Q2 2019 | $299,645 | -19.9% | 41,850 | +48.5% | 0.00% | -25.0% |
| Q1 2019 | $374,204 | +68.7% | 28,178 | 0.0% | 0.00% | +33.3% |
| Q4 2018 | $221,761 | -29.0% | 28,178 | 0.0% | 0.00% | 0.0% |
| Q3 2018 | $312,212 | -17.4% | 28,178 | 0.0% | 0.00% | -25.0% |
| Q2 2018 | $378,000 | – | 28,178 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 1,629,464 | $14,208,926 | 10.61% |
| Lynx1 Capital Management LP | 1,369,927 | $11,945,763 | 9.96% |
| Versant Venture Management, LLC | 543,753 | $4,741,526 | 9.88% |
| Foresite Capital Management IV, LLC | 1,787,094 | $15,583,460 | 8.09% |
| Octagon Capital Advisors LP | 4,570,918 | $39,858,405 | 5.74% |
| ACUTA CAPITAL PARTNERS, LLC | 878,500 | $7,660,520 | 5.64% |
| TCG Crossover Management, LLC | 3,048,257 | $26,580,801 | 5.18% |
| Affinity Asset Advisors, LLC | 1,083,118 | $9,444,789 | 3.12% |
| Altium Capital Management LP | 620,000 | $5,406,400 | 3.00% |
| Bain Capital Life Sciences Investors, LLC | 2,500,000 | $21,800 | 2.72% |